Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

StemVax secures patent for brain cancer vaccine
October 2018
SHARING OPTIONS:

CLEVELAND—The third quarter of 2018 saw StemVax Therapeutics, an Innovest Global Inc. holding, receive an exclusive worldwide license agreement from Cedars-Sinai Medical Center for all intellectual property (IP) necessary for commercializing StemVax’s Glioblast brain tumor vaccine. Cedars-Sinai filed for a patent to the primary technology, which Innovest announced had been approved in July 2018, and has granted StemVax the exclusive worldwide right to the patent, as well as three related IPs filed for patent protection.
 
“The StemVax business model is a low cost, high output strategy of partnering with a major health organization to get the technology to market and start helping people,” said Dr. Dwain Morris-Irvin, president of Innovest’s Biotech Division, StemVax’s chief science officer and co-author of the IP. “This agreement, which was negotiated over a nine-month period, is critical because we now have everything we need, and we have it all in house.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.